Template:Rifampin isoniazid pyrazinamide: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Gerald Chi moved page Template:Isoniazid to Template:Rifampin isoniazid pyrazinamide without leaving a redirect)
mNo edit summary
Line 1: Line 1:
{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
|-
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Isoniazid|{{fontcolor|#6C7B8B|Isoniazid}}]]'''''
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Isoniazid|{{fontcolor|#6C7B8B|Isoniazid}}]]'''''
|-
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left |RIFATER <sup>®</sup> FDA Package Insert
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left |RIFATER <sup>®</sup> FDA Package Insert
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Isoniazid description|Description]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide description|Description]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Isoniazid clinical pharmacology|Clinical Pharmacology]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide clinical pharmacology|Clinical Pharmacology]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Isoniazid microbiology|Microbiology]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide microbiology|Microbiology]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Isoniazid indications and usage|Indications and Usage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide indications and usage|Indications and Usage]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Isoniazid contraindications|Contraindications]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide contraindications|Contraindications]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Isoniazid warnings and precautions|Warnings and Precautions]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide warnings and precautions|Warnings and Precautions]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Isoniazid adverse reactions|Adverse Reactions]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide adverse reactions|Adverse Reactions]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Isoniazid overdosage|Overdosage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide overdosage|Overdosage]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Isoniazid clinical studies|Clinical Studies]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide clinical studies|Clinical Studies]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Isoniazid dosage and administration|Dosage and Administration]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide dosage and administration|Dosage and Administration]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Isoniazid how supplied|How Supplied]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide how supplied|How Supplied]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Isoniazid labels and packages|Labels and Packages]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide labels and packages|Labels and Packages]]
|-
|-
|}
|}

Revision as of 14:25, 31 December 2013

Isoniazid
RIFATER ® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages
Retrieved from "https://www.wikidoc.org/index.php?title=Template:Rifampin_isoniazid_pyrazinamide&oldid=921958"